« Return to News | CROs/Service Providers

Kendle's Global CRO Growth Story Continues with Record Quarter

Thursday, August 7, 2008 07:30 AM

On a day when contract research organization (CRO) Covance announced a blockbuster $1.6 billion deal with Eli Lilly, the global CRO growth story got another big boost when Kendle reported record financial results for its second quarter.

Kendle’s shares closed up 11.7% Wednesday at $45.36.

Net service revenues for the three months ended June 30 jumped 30% to $127 million, compared with $97.8 million for the same period a year ago. The acquisition of DecisionLine Clinical Research accounted for approximately 2% of the growth.

Net income per diluted share for the second quarter 2008 was $0.52 per share, up 79% from $0.29 for the same period of the prior year.

New business awards for second quarter 2008 were $204 million, a 24% increase compared with the same quarter last year. Contract cancellations for the quarter were $27 million.

"Kendle delivered a strong performance for the second quarter," said Candace Kendle, PharmD, chairman and CEO of Kendle. "We remain focused on our strategic customer development and business expansion initiatives to drive continued growth in our business and increased profitability and value for our shareholders."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.